Pharmacotherapy Update
Journavx (suzetrigine)
On January 30, 2025, the US Food and Drug Administration (FDA) approved Journavx (suzetrigine), a non-opioid analgesic, for the management of moderate-severe acute pain. Journavx is the first drug to be approved that targets the voltage-gated sodium channel NaV1.8. This novel target marks a new therapeutic class of non-opioid analgesics.
Published online March 31, 2026.
Bookmark this page and check back often for papers published early online.